Healthcare Webinars

Welcome from the ChairIt is my great pleasure to host the second webinar of Dermatopathology, which will be on the topic of “Oral leukoplakia: Are they all dysplastic in the molecular age?“ This webinar will be of interest to dermatopathologists and pathologists signing out oral biopsies. We have, as a speaker, the distinguished Prof. Sook-Bin Woo from the Harvard School of Dental Medicine. She has been a Professor at the Harvard School of Dental Medicine and Harvard Medical School since 2008. Prof. Woo is the Graduate Program Director for the Oral and Maxillofacial Pathology specialty training program. She has served on the Fellowship Committee and Executive Council of the American Academy of Oral and Maxillofacial Pathology and on the board of the American Academy of Oral Medicine, where she was President of the Board from 2014 to 2015. She has published numerous scholarly papers, book chapters and a textbook and is reviewer for many journals. She is a much sought-after speaker at many national and international conferences and teaches many courses. Prof. Woo has received the National Research Service Award from the NIH, the American Cancer Society Career Development Award, and the Distinguished Senior Faculty Award from the Harvard School of Dental Medicine, among other honors. I would like to thank Prof. Woo for her participation in our second webinar and hope to continue with these webinars in the future, which I am sure will be highly beneficial for the readers of Dermatopathology and members of the European Society of Dermatopathology.Date: 12 September 2024 at 3:30 p.m. CEST | 9:30 a.m. EDT | 9:30 p.m. CST AsiaWebinar ID: 867 6706 9689Webinar Secretariat: journal.webinar@mdpi.comThis is a FREE webinar. After registering, you will receive a confirmation email containing information on how to join the webinar.  Registrations with academic institutional email addresses will be prioritized.Certificates of attendance will be delivered to those who attend the live webinar.Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.Speakers: Prof. Dr. Gürkan Kaya - University Hospital of Geneva and Prof. Dr. Sook-Bin Woo - Harvard School of Dental Medicine.

Enhancing adeno-associated virus (AAV) viral vector quality can significantly impact product efficacy and is essential to ensure patient safety. We invite you to join our team of experts for a deep dive into our AAV viral vector development expertise and showcase our recent breakthroughs.In this webinar, our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and, consequently, the potency of AAV products:We will first present how VP1 deamidation, which has been associated with a decrease in potency, is also connected to hydrophobicityWe will investigate how production time within the bioreactor and AAV location inside or outside the cell affects capsid post-translational modifications and surface chargeWe will finally demonstrate the importance of reducing and controlling the level of intermediate (partially full) and empty capsids, which can impact product efficacy and have potential implications for patient safetyAfter the webinar, we will host a live Q&A session, providing attendees with the opportunity to ask questions directly to the presenters. We look forward to your participation.Who Should Attend?This webinar will appeal to professionals in the following fields or those having the following job titles:Biotechnology and pharmaceutical professionalsProject Managers/Technical ExpertsResearch & DevelopmentCell and Gene Therapy Program LeadersBusiness DevelopmentAcademicsWhat You Will LearnAttendees will learn about:Negative charge due to deamidation and hydrophobicity are related and impact capsids separationProduction duration and location of capsids at harvest affect AAV charge and potencyHow although intermediate capsids contribute to overall titer and are infectious, their payloads are not efficacious and thus considered a process-related impuritySpeakers: Sarah Laughlin-Toth - Senior Scientist II Analytical Development, Oxford Biomedica; Thomas Thiers - Scientist II Purification Sciences, Oxford Biomedica; Alex Meola - Associate Director, AAV Downstream Process Development, Oxford Biomedica.

In this webinar, Dr. Buckley presents the sex differences in dementia, focusing on diagnosis, tauopathy, and implications for clinical trials.This presentation highlights the state of play in the literature with regard to sex differences in prevalence and incidence rates of dementia. Dr. Buckley touches upon the well characterized issue of women being underdiagnosed with dementia due to the fact that they perform much better than men on many neuropsychological tests. She presents her work that has shown consistently, and across many independent cohorts, that women show elevated levels of tauopathy in the brain relative to men. After demonstrating these sex differences in these clinical AD-related outcomes, she turns to the question of whether they might be driven by sex steroid hormones or the X chromosome. She ends the talk by touching upon the reasons why we care about sex differences, particularly from a clinical trials perspective. In addition, she presents her working framework for where she thinks the field stands and what gaps remain in the literature.Key Topics Include:The extent to which sex differences exist in Alzheimer’s disease riskHow sex steroid hormones and the X chromosome play a role in moderating this riskUnderstand the importance of sex disaggregating findings, both in observational research and also in clinical trialsPresenter: Rachel Buckley, PhD - Associate Professor, Neurology, Massachusetts General Hospital.

Join us for a webinar that explores the world of vaccines. Learn about the ingredients, the development process, and the safety measures in place.Dr. Ryan Hassan of Boost Oregon will be joining us to discuss vaccine ingredients and safety. We welcome anyone interested in learning more about how vaccines are developed.

Please note that this event is for Victorian residents only.This EDV Community Webinar is a 1 hour online workshop that will explore and aim to provide understanding of Perfectionism. This webinar is suitable for anyone currently experiencing or has recovered from an eating disorder, carers and support people, and those in the general community who are wanting to learn more about perfectionism.You can expect a balance of education and the opportunity for reflection, with a focus on the following topics: • Defining Perfectionism• Perfectionism and Eating Disorders• The Paradox of Perfectionism• Strategies to Manage PerfectionismYour facilitators:Emilie - Senior Education OfficerEmilie has worked within mental health services for twelve years with both adults and children both in the United Kingdom and Australia. Emilie is passionate about the importance of meaningful connection in her work and personal life, which was paramount in her own recovery of a severe and enduring eating disorder, and continues to be one of her core values. Abbey - Education OfficerAbbey has a background in public health and health promotion, and has worked in the mental health space for the past four years. Through experiencing and recovering from an eating disorder, Abbey realised her passion for raising awareness in the community about eating disorders and other mental health conditions, and is proud to be able to continue this work as part of the EDV Education Team. Shaan - Postgraduate Student, Master of Public HealthShaan is undertaking the final part of her Master of Public Health on placement at Eating Disorders Victoria. The work that EDV does sits close to Shaan’s heart, having herself experienced and recovered from an eating disorder. Shaan is excited to be bringing her public health knowledge and lived experience, along with four years’ public service experience in education, to the Education Team at EDV. WhenMonday September 9th, 2024 - 12:00pmWhere The webinar will take place via Zoom, with Zoom link details to be sent to attendees two hours prior to the event start time. Participants are not required to have their cameras or microphones on for this webinar, and are welcome to ask any questions anonymously throughout. This webinar will be recorded and will be made available to people who have registered for this webinarCostFree to attendEnquiriesFor more information or enquiries, please contact education@eatingdisorders.org.auYou will receive an email with the information on how to join 2 hours before the event. Please check your email, your junk email and any other email addresses that you might use. If you do not have an email then please contact us. The information you provide to Eating Disorders Victoria is for the purpose of contacting you about this event and to evaluate our services and client needs, with the view of improving our services. 

When sick children arrive at primary health care facilities, it is critical that they are appropriately screened, diagnosed, managed, and if needed, referred for urgent care without delay. Clinical signs alone do not detect all severe illness in children. For health care providers to make a correct diagnosis, they must be equipped with the right tools, including access to pulse oximetry and clinical decision support systems. In many countries, these critical tools are not available, not functioning properly, or providers lack appropriate training. There is also no clear global guidance to help countries in choosing the best devices, nor is information available on their cost-effectiveness or suitability in primary care.Between 2019 and 2024, the Tools for Integrated Management of Childhood Illness (TIMCI) initiative, led by PATH in collaboration with a consortium of partners and funded by Unitaid, worked together with the governments of India, Kenya, Senegal, and Tanzania to improve access to critical tools that help frontline health workers identify and appropriately manage children who are severely ill. This work included large-scale, multi-country, mixed-method evaluation conducted to address evidence gaps and inform national and international decision-making on scale-up of pulse oximetry and clinical decision support algorithms.Join us to review the cross-country results, interpretations, as well as key takeaways from the TIMCI studies, which can be helpful to decision-makers and implementers in further assessing national and global strategies for effectively embedding pulse oximetry and CDSAs as part of wider efforts to strengthen quality of care.

Churchill once said, “Out of intense complexities, intense simplicities emerge.”He meant that during challenging times, extreme focus reveals solutions right in front of companies. Despite ongoing tech investments, only 1 in 10 drugs gets commercialized, with costs soaring. Healthcare and life sciences companies are struggling and need future-proof ways to unlock organizational creativity. Worse, less than 20% of executives feel prepared to handle increasing complexities and challenges.What if you could connect people, departments, functions, and ecosystems to drive successful outcomes with a unified digital foundation? What if you could reignite innovation, reach more patients, and control costs?Introducing ServiceNow’s Digital Health Platform: a unified, industry-centric solution enabling H&LS customers to meet global disruption challenges.Save your seat and learn how to advance life sciences by leveraging EY’s expertise and ServiceNow’s transformative offerings.

Sign up for the webinar and join Mr. Michael Horler, Mrs. Samantha Mann, and Prof. Tunde Peto as they discuss the inclusion of the OCT pathway in DESP and its benefits and challenges.Program• Introduction – Mr. Michael Horler• The New OCT Pathway: Why Was Adding This Pathway Necessary? | Mrs. Samantha Mann• Cases 1-2: Representative Cases | Mrs. Samantha Mann and Prof. Tunde Peto• The South London Experience | Mrs. Samantha Mann• Case 3: From South London | Mrs. Samantha Mann• Analysing OCT Images and Getting Ready for the DESP Pathway Change | Prof. Tunde Peto• Cases 4-5: The One Where the Pathway Will Help and the One Where It Will Not! | Prof. Tunde Peto• Live Q&A moderated by Mr. Michael HorlerWhy should you attend?• Discover how OCT will change diabetic eye screening• Get practical tips and learn how to interpret OCT images• Get more insights into what OCT is• Participate in the live Q&A to find answers to your questionsSpeakers: Mrs. Samantha Mann, MD MRCOph FRCOph and Prof. Tunde Peto, MD, PhD.------------Prepare for the integration of the OCT pathway into the English National Diabetic Eye Screening Programme (DESP) and join our webinar on September 4 at 6 pm (UK time) / 7 pm (CEST).This 90-minute event, made possible by the Canon Medical Academy, will cover the benefits, challenges, and essential training for accurate OCT image grading.Designed by eye care professionals for eye care professionals, this event is crucial for mastering advancements in diabetic retinopathy management. The inclusion of the OCT pathway in DESP represents a significant leap in diabetic eye care, offering more efficient and accurate screening while reducing the pressure on hospital eye services.Register now to improve your skills and stay ahead in retinal screening with our expert-led webinar.

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s Medical Affairs team for this webinar to hear about tissue stewardship from a pathologist and oncologist’s perspectives. We will review our latest data from advanced NSCLC which demonstrate that single-gene testing, if performed prior to comprehensive genomic profiling, doubles comprehensive genomic profiling failures due to tissue insufficiency and DNA extraction failures. We will share best practices to optimize tissue utilization and ensure patients with advanced NSCLC receive all recommended biomarker testing.Learning Objectives:• Describe the various tissue testing methodologies available for evaluation of biomarkers for patients with advanced NSCLC.• Compare biomarker testing paradigms with single gene testing and comprehensive genomic profiling to describe benefits and pitfalls of each strategy.• Integrate best practices for tissue stewardship to optimize biomarker testing in advanced NSCLC.Speakers: Kyle Strickland, MD, PhD (Labcorp Oncology, Director, Medical Affairs and Adjunct Associate Professor, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Labcorp), Rebecca Previs, MD, MS (Labcorp Oncology, Director, Medical Affairs and Adjunct Assistant Professor, Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Labcorp).

Manufacturing cell and gene therapy products is complex and involves multiple challenges, including a unique combination of expensive cell culture solutions and experience. It is crucial to keep the end product in mind from the beginning in order to expedite processes and ensure a seamless scale-up, while reducing costs. Optimizing cell culture media and buffers to fit your process allows you to enhance experimental conditions, improve cell performance, and achieve more reliable and reproducible results in your studies.  In this webinar, our experts will discuss the importance of optimized cell media and buffers using the design of classical media formulations to demonstrate the importance of component selection in the formulation process. Our collaborators at University of Pennsylvania and SK pharmteco will explain how media and buffer design has optimized their processes and improved outcomes. You will learn how cell media and buffers can impact cell growth, viability, and therapeutic efficacy as well as strategies to simplify custom media and buffer design and optimization for all stages of development and manufacturing.  Key Takeaways: • Understand how customized media and buffers can optimize CQAs in C&GT. • Explore real-world case studies demonstrating the impact of customized solutions. • Gain practical insights into improving bioprocess development and consistency. Speakers: Asma Ayari, Ph.D., Director of Research and Development, Nucleus Biologics; John Bowen, Ph.D., Senior Director of Nucleic Acids and Plasmid Operations, SK pharmteco; Roddy O’Connor, Ph.D., Research Assistant Professor, Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine.